GLYCOSTEM THERAPEUTICS
Netherlands-based Glycostem Therapeutics BV, a clinical stage biotech company focused on developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells to treat several types of cancer. NK-cells are the body’s first line of defence because of the innate ability of NK-cells to rapidly and accurately identify and destroy cells under stress, such as cancer or virally-infected cells. Glycostem’s lead product, oNKord® , is produced in a closed system in Glycostem’s ... state-of-theart production facility in The Netherlands, from which the product can be distributed globally. The platform technology includes ex vivo expansion of a high number of pure and highly activated NK-cells for clinical applications. oNKord® successfully concluded phase I clinical trial (elderly and fragile AML patients), providing solid safety data and strong indication of clinical activity, including response on MRD. Glycostem expects to obtain GMP certification by the end of 2018 and is planning to enter pivotal clinical trial in Q1 2019. Thanks to the six patent families, longstanding technical expertise and resources, as well as ‘Orphan Drug Designation’, Glycostem has secured a leadership position in the global NK-cell market.
GLYCOSTEM THERAPEUTICS
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2007-01-01
Address:
Oss, Noord-Brabant, The Netherlands
Country:
The Netherlands
Website Url:
http://www.glycostem.com
Total Employee:
11+
Status:
Active
Contact:
+31 (0) 412 211 001
Technology used in webpage:
Google Maps ReCAPTCHA V2 3 To 9 CcTLD Redirects
Current Employees Featured
Troels Jordansen Chief Executive Officer @ Glycostem Therapeutics
Chief Executive Officer
2016-07-01
Jan Spanholtz Chief Scientific Officern & Founder @ Glycostem Therapeutics
Chief Scientific Officern & Founder
2007-01-01
Volker Huppert Chief Development Officer @ Glycostem Therapeutics
Chief Development Officer
Didier Haguenauer Chief Medical Officer @ Glycostem Therapeutics
Chief Medical Officer
Hans Henskens Chief Quality Officer @ Glycostem Therapeutics
Chief Quality Officer
Virginie Bonnamain Medical Director @ Glycostem Therapeutics
Medical Director
2020-07-01
Kai Pinkernell Chief Medical Officer @ Glycostem Therapeutics
Chief Medical Officer
2021-04-01
Founder
Official Site Inspections
http://www.glycostem.com Semrush global rank: 6.83 M Semrush visits lastest month: 755
- Host name: vip.reactonline.nl
- IP address: 87.233.157.142
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "Glycostem Therapeutics"
Home page | glycostem
Glycostem is developing a pipeline of cellular immunotherapy therapies, which has the potential to redefine standards of care across various type of cancer. Besides of oNKord ® as our lead …See details»
Investor - glycostem
Our organization is guided by a highly experienced Management Team and Board of Directors and supported by a Scientific Advisory Board that includes renowned experts in the field of innovative cancer therapeutics. Moreover, …See details»
Taking cellular immunotherapy to the next level - glycostem
Glycostem signs global CAR-NK product co-development deal 11th Sep ’19 Glycostem out-license oNKord® for Korea and Japan 9th Sep ’19 Glycostem raises €14 million in equity Sep …See details»
Glycostem Therapeutics - Crunchbase Company Profile & Funding
Glycostem expects to obtain GMP certification by the end of 2018 and is planning to enter pivotal clinical trial in Q1 2019. Thanks to the six patent families, longstanding technical expertise and …See details»
Glycostem Therapeutics - LinkedIn
Glycostem Therapeutics is a Dutch biotech company established in 2007. Glycostem Therapeutics has developed the world's first GMP compliant NK cell platform that is ready for …See details»
Glycostem - VentureRadar
" Glycostem Therapeutics’ core competence is the production of NK-cells for cellular immunotherapy from umbilical cord blood (UCB). The company has developed a unique GMP …See details»
Glycostem Therapeutics B.V. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Glycostem Therapeutics B.V. of Oss, Noord-Brabant. Get the latest business insights from Dun & Bradstreet.See details»
Glycostem Therapeutics B.V. - BLSF
Glycostem Therapeutics B.V. is a Dutch life science company that develops cellular immune therapies for the treatment of leukemia and other forms of cancer. The company has …See details»
Glycostem Therapeutics - Crunchbase
Glycostem is a clinical stage biotech company developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells. Search Crunchbase. Start Free Trial . Chrome …See details»
Glycostem and Ghent University sign license agreement on NK cell ...
Dec 17, 2020 /PRNewswire/ -- Glycostem Therapeutics B.V., ... Our organization is dedicated to research and innovation with over 5,500 researchers active in a wide area of life, physical and …See details»
Glycostem Therapeutics - Contacts, Employees, Board Members, …
Glycostem is a clinical stage biotech company developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells. Search Crunchbase. Start Free Trial . Chrome …See details»
Glycostem Therapeutics B.V. - BIO International Convention | BIO
Jun 5, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Glycostem …See details»
Glycostem Company Profile - Office Locations, Competitors ... - Craft
Glycostem is a company specializing in allogeneic cellular immunotherapy. It uses allogeneic cells like Natural Killer (NK) cells for the treatment of leukemia, lymphoma, and solid tumors. The …See details»
Glycostem - media.nature.com
Glycostem’s biobank and shipped to any patient anywhere in the world, or held in hospitals. Glycostem is open to developing collaborations and has a strategy that enables partnerships …See details»
Glycostem - Overview, News & Similar companies | ZoomInfo.com
May 13, 2022 Glycostem and medac enter into license, manufacturing, supply and commercialization agreement for Glycostem's lead product - oNKord® OSS, Netherlands, …See details»
Glycostem Therapeutics - Dulisco
Glycostem is a clinical-stage company, harvesting the power of allogeneic cells like Natural Killer (NK) cells – oNKord® – in the field of cellular immunotherapy. Using our proprietary expansion …See details»
Taking cellular immunotherapy to the next level - glycostem
Glycostem raises €14 million in equity Sep ’19 Glycostem raises €5 million for clinical trials 25th June ’19 Glycostem receives GMP license Glycostem Therapeutics B.V. Kloosterstraat 9, …See details»
Glycostem Therapeutics - Tech Stack, Apps, Patents & Trademarks
Organization. Glycostem Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 37. ... Additionally, …See details»
glycostem
20 th April 2023 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, has announced …See details»
Science and Technology - glycostem
Glycostem presented three posters demonstrating our novel NK cell therapeutics at the 19th Meeting of the Society for Natural Immunity (NK2022). Click on the links below to download …See details»